<html><head><script id="decision-support-view" type="application/json">{
  "dsViewId": "Lipid_modification_therapy_follow_up_and_monitoring.v0",
  "language": {
    "originalLanguage": {
      "terminologyId": {
        "name": "ISO_639-1",
        "value": "ISO_639-1"
      },
      "codeString": "en"
    }
  },
  "decisionSupportViewDefinitions": {
    "sv": {},
    "en": {
      "name": "Lipid modification therapy follow up and monitoring",
      "description": "NICE Guidelines on lipid modification therapy among patients with diabetes"
    }
  },
  "resourceDescription": {
    "originalAuthor": {
      "date": "2017-07-16",
      "name": "Dennis Forslund",
      "organisation": "Cambio Healthcare Systems",
      "email": "models@cambiocds.com"
    },
    "otherContributors": [],
    "details": {
      "sv": {
        "purpose": "*(en) To provide guidance on lipid modification therapy including follow-up and monitoring among patients with type 2 diabetes, in accordance with the NICE Guidelines.",
        "keywords": [
          "*(en) NICE",
          "*(en) NICE guidelines",
          "*(en) diabetes",
          "*(en) lipids",
          "*(en) statin",
          "*(en) HDL",
          "*(en) LDL",
          "*(en) cholesterol"
        ],
        "use": "*(en) Use to provide guidance on lipid modification therapy including follow-up and monitoring among patients with type 2 diabetes, in accordance with the NICE Guidelines.",
        "copyright": "Cambio Healthcare Systems"
      },
      "en": {
        "purpose": "To provide guidance on lipid modification therapy including follow-up and monitoring among patients with type 2 diabetes, in accordance with the NICE Guidelines.",
        "keywords": [
          "NICE",
          "NICE guidelines",
          "diabetes",
          "lipids",
          "statin",
          "HDL",
          "LDL",
          "cholesterol"
        ],
        "use": "Use to provide guidance on lipid modification therapy including follow-up and monitoring among patients with type 2 diabetes, in accordance with the NICE Guidelines.",
        "copyright": "Cambio Healthcare Systems"
      }
    },
    "otherDetails": {
      "references": "National Institute for Health and Clinical Excellence (2015) Type 2 diabetes in adults: management. NICE guideline (NG28)."
    }
  },
  "alertGuideIds": [],
  "executionGuideIds": [
    "Lipid_modification_therapy_follow_up_and_monitoring.v0"
  ],
  "alertBindings": {},
  "termDefinitions": {
    "sv": {
      "id": "sv",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "*(en) References"
        }
      }
    },
    "en": {
      "id": "en",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "References"
        }
      }
    }
  },
  "resultTemplates": []
}</script></head><body></body></html>